Open-label, multi-center, phase II study of adjuvant pemetrexed plus cisplatin for completely resected stage IB to IIIA adenocarcinoma of the lung: APICAL trial

BACKGROUND: We aimed to evaluate the efficacy of postoperative adjuvant pemetrexed plus cisplatin (Pem-Cis) in pathologic stage IB–IIIA lung adenocarcinoma (LUAD) patients. METHODS: A prospective, phase II study was performed in seven institutions in South Korea. Patients with completely resected st...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Cheol-Kyu, Oh, Hyung-Joo, Yoo, Seung Soo, Lee, Shin Yup, Lee, Sang Hoon, Kim, Eun Young, Lee, Sung Yong, Choi, Juwhan, Lee, Min Ki, Kim, Mi-Hyun, Jang, Tae Won, Chung, Chaeuk, Oh, In-Jae, Kim, Young-Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459613/
https://www.ncbi.nlm.nih.gov/pubmed/36090637
http://dx.doi.org/10.21037/tlcr-22-183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459613/
https://www.ncbi.nlm.nih.gov/pubmed/36090637
http://dx.doi.org/10.21037/tlcr-22-183

Ejemplares similares